Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030626 | 0.91 | GAA (0.39) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| SCHEMBL19009972 | 0.87 | HSD11B1 (0.30) | — | |
| SCHEMBL5897025 | 0.86 | MAPT (0.32) | ALDH1A1GAAMAPT | |
| SCHEMBL29597288 | 0.83 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL12446368 | 0.83 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL5897034 | 0.81 | AKT1 (0.33) | CYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL13338228 | 0.80 | CYP3A4 (0.33) | CYP3A4TDP1DRD1ALDH1A1GAA | |
| SCHEMBL7552025 | 0.80 | ADORA2A (0.31) | — | |
| SCHEMBL17426096 | 0.79 | CYP3A4 (0.38) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL31566366 | 0.76 | CYP3A4 (0.35) | CYP3A4TDP1DRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-2774908-B1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO PERFUMERY CO LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9255049-B2 | Ruthenium complex and method for preparing optically active alcohol compounds using the same as a catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9079931-B2 | Ruthenium complex and method for preparing optically active alcohol compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2563799-B1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-02-11 | — | — | EP | disclosed |
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2774908-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | Takasago International Corporation (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2695887-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | Takasago International Corporation (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| US-7038087-B2 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
| EP-0860432-B1 | 2-Phenyl-2-(2'-piperidinylidene) acetate derivative, process for manufacturing the same, and process for manufacturing optically active 2-phenyl-2(2'-piperidinyl) acetate derivative by asymmetrically hydrogenating the same | TAKASAGO PERFUMERY CO LTD (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-5859249-A | CYCLIZATION A 7-(N-SUBSTITUTED AMINO)-3-OXO-2-PHENYLHEPTANOATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5801271-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0860432-A1 | 2-Phenyl-2-(2'-piperidinylidene) acetate derivative, process for manufacturing the same, and process for manufacturing optically active 2-phenyl-2(2'-piperidinyl) acetate derivative by asymmetrically hydrogenating the same | Takasago International Corporation (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | QDPR, NOX4, NOX5 | CYP3A4 731/4885TDP1 3730/4885DRD1 1239/4885 |
| US-20130041151-A1 | RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH5, ADH1C, ADH1A | CYP3A4 20/4885TDP1 4056/4885DRD1 121/4885 |
| US-20140187809-A1 | NOVEL RUTHENIUM COMPLEX AND PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND USING SAME AS CATALYST | ADH1C, ADH5, ADH1A | CYP3A4 31/4885TDP1 4367/4885DRD1 117/4885 |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | HRH3, HRH1, ATIC | CYP3A4 863/4885TDP1 2900/4885DRD1 61/4885 |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | CYP3A4 224/4885TDP1 4184/4885DRD1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.